ACUTE PANCREATITIS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025 - 2032)

Global Acute Pancreatitis Market Size and Forecast – 2025 to 2032

The global acute pancreatitis market is estimated to be valued at USD 3.62 Bn in 2025 and is expected to reach USD 5.41 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 5.9% from 2025 to 2032. This growth reflects increasing prevalence of pancreatitis due to rising incidences of gallstones, alcohol consumption, and obesity worldwide, along with advancements in diagnostic scan tools and therapeutic options driving market expansion over the forecast period.

Key Takeaways of the Global Acute Pancreatitis Market

• In 2025, gallstone-induced cases are expected to represent the leading segment of the global acute pancreatitis market, accounting for 42.1% of total market share.
• Drug based therapy is projected to dominate the treatment landscape with a 55.3% share in 2025.
• Oral route of administration is expected to hold the largest portion at 75.9% in 2025.
• North America is expected to lead the market, holding a share of 38.9% in 2025. Asia Pacific is anticipated to be the fastest-growing region, with an estimated market share of 24.4% in 2025.

Market Overview

Key market trends include a growing focus on minimally invasive treatment techniques and personalized medicine, which enhance patient outcomes and reduce hospitalization times. Additionally, increased healthcare expenditure and awareness campaigns are fueling early diagnosis and treatment adoption. Technological advancements in imaging and intervention methods, combined with strategic collaborations among pharmaceutical and medical device manufacturers, are poised to further propel market growth and innovation in managing acute pancreatitis.

Current Events and Its Impact

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Segmental Insights

To learn more about this report, Download Free Sample

Acute Pancreatitis Market Insights, By Etiology - Gallstone-induced Etiology Dominates Due to its Rising Prevalence and Diagnostic Advancements

Gallstone-induced pancreatitis in terms of etiology, is expected to hold the largest share of 42.1% in the global acute pancreatitis market in 2025. This is mainly because gallstones are the most common cause of acute pancreatitis and the prevalence of gallstones is very high all over the world. When gallstones get stuck in the pancreatic duct, the pancreatic enzymes get activated way too early and inflammation follows.

Plus, another important factor is that the diagnostic technologies like ultrasound and Magnetic Resonance Cholangiopancreatography, are very advanced now and widely available. These methods allow early and accurate detection of gallstones thus, the timely intervention is possible, and the treatment recommendations are influenced.

Acute Pancreatitis Market Insights, By Treatment Type - Drug-Based Therapy Leads Owing to Therapeutic Versatility and Supportive Care Needs

In the type of segmentation treatment of the global acute pancreatitis market, drug based therapy is the one that has the biggest share, holding an estimated 55.3% of the market share in 2025. This segment is leading because of the need for a multi-faceted approach that is drug-based to manage acute pancreatitis; that is, using drug-based therapies like analgesics, antiemetics, proton pump inhibitors (PPIs), somatostatin analogues, and IV fluids to control symptoms, decrease inflammation, and avoid complications.

In July 2024, the U.S. FDA granted Fast Track status to RABI-767, developed by RAbil Therapeutics, for treating acute pancreatitis likely to progress to severe disease. The investigational lipase inhibitor, delivered via endoscopic ultrasound injection, aims to prevent organ failure and improve survival in high-risk patients.

Acute Pancreatitis Market Insights, By Route of Administration - Oral Route Prevails Due to Patient Compliance and Outpatient Management Trends

In the context of administration paths, the oral segment represents the largest part of the global acute pancreatitis market with an estimated 75.9% of the market share in 2025. This dominance is a result of several patient’s convenience factors, prevailing clinical practices, and the nature of the drugs employed. Oral administration is normally the preferred route of drug delivery when it is possible because among other benefits it has ease of use, improved patient compliance, and less use of healthcare resources as compared to parenteral routes.

The oral route is often employed for the administration of several drugs that are prescribed in acute pancreatitis therapy, like pancreatic enzyme supplements, proton pump inhibitors, and analgesics. The emergence of such formulations with better bioavailability and fewer side effects opens up the oral route as a viable choice for a large patient population.

Regional Insights

To learn more about this report, Download Free Sample

North America Acute Pancreatitis Market Analysis and Trends

Countries in North America have the best healthcare infrastructure that caters to the global acute pancreatitis market and this will be reflected by their estimated market share of 38.9% in 2025. Besides, there are robust research and development activities going on in the region and the presence of large pharmaceutical and biotech companies is also significant. The region is also very fortunate to have government support in areas such as healthcare funding and regulatory policies that are favorable to the research and development of new treatments.

For instance, according to a November 2022 article by the National Library of Medicine, acute pancreatitis has become the most common gastrointestinal condition and a leading cause of hospitalization in the U.S. A July 2022 MedRxiv study reported that gallstone disease accounted for about 2.2 million ambulatory visits, 1.1 million emergency department visits, and 615,000 hospital discharges in the country, with women showing a higher prevalence than men.

Asia Pacific Acute Pancreatitis Market Analysis and Trends

The Asia Pacific region is projected to be the fastest-growing market for acute pancreatitis medications, holding a 24.4% share in 2025. This growth is driven by rising healthcare expenditure, an increasing prevalence of the disease, and improved access to medical care in developing economies across the region. The governments in countries such as China, India, and Japan are gradually upgrading healthcare facilities and executing policies that enable pharmaceutical companies to innovate and to enter the market more easily.

The growing number of people in the middle class and the rising awareness about pancreatic health are factors that urge the demand for better diagnostics and innovative treatments. Moreover, the region’s industrial presence has also grown with companies like Takeda Pharmaceutical, Sun Pharmaceutical, and Ono Pharmaceutical being present here, which are not only investing in local research and development but also forming strategic partnerships to meet the needs of the region.

Global Acute Pancreatitis Market Outlook for Key Countries

U.S. Acute Pancreatitis Market Trends

The U.S. remains the forerunner in the treatment of acute pancreatitis, largely due to its world-class healthcare system and consistent investment in medical research. The foremost pharmaceutical companies, namely AbbVie, Pfizer, and Johnson & Johnson, are in continuous clinical trials to discover new drugs. Alongside the regulatory agencies, insurances are also willing to cover the costs of diagnosis and disease management; thus, the early diagnosis and proper treatment are given the green light.

Building on this momentum, research collaborations are gaining traction across the U.S., exemplified by the Phase I/II trial initiated in December 2022 by St. Jude Children’s Research Hospital in partnership with CalciMedica Inc. to assess CM4620 in children and young adults with asparaginase-induced acute pancreatitis, highlighting the country’s strong commitment to advancing innovative drug and device-based treatment solutions.

China Acute Pancreatitis Market Trends

The acute pancreatitis market in China is growing at a fast pace, which is backed up by the government’s healthcare reform and the increasing investment of the public sector in the medical infrastructure. Moreover, the rising number of cases and improved screening programs have together led to more people being diagnosed and better management of the disease. Furthermore, collaboration with international companies help in the transfer of technology and adoption of innovation, thus increasing the presence of China in the market.

Leading Chinese firms such as Harbin Pharmaceutical Group, Shanghai Pharmaceuticals, and Shenzhen Mindray Bio-Medical Electronics Co., Ltd. are strengthening diagnostic and therapeutic infrastructure through product development and hospital partnerships. International collaborations—like those between AstraZeneca and WuXi AppTec support technology transfer and innovation in drug development for pancreatic inflammation and related gastrointestinal disorders.

Germany Acute Pancreatitis Market Trends

With its advanced healthcare system and a focus on delivering high-quality patient care, Germany is still the number one country in Europe. The stability of the pharmaceutical industry and the government support for innovation are the two factors that keep the market on a steady path to growth. Besides, the clinical research in Germany is very strong and the study of new therapies for acute pancreatitis is expedited and the nationwide protocols of therapy are also improved.

Germany’s leadership in the Europe acute pancreatitis market is reinforced by companies such as Bayer AG, Boehringer Ingelheim, and Fresenius SE & Co. KGaA, which drive pharmaceutical innovation and hospital care advancements. Partnerships between German research institutes and global firms like Roche and Novartis accelerate the adoption of precision medicine and clinical trial activity related to inflammatory and digestive diseases, including acute pancreatitis.

India Acute Pancreatitis Market Trends

The market for acute pancreatitis in India is changing because of the country’s increased healthcare spending and the opening up of avenues for people to receive quality medical care. The government is trying to provide everyone with healthcare and at the same time, there are more and more private clinics making treatment easier to access. The awareness of the diseases of the pancreas is on the rise thus upholding the concept of early diagnosis, while the biopharma industry is growing which in turn brings forth innovations and market expansion.

India’s growing market benefits from strong domestic pharmaceutical firms such as Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories, and Cipla Ltd., which focus on affordable gastrointestinal therapies and supportive care products. Collaborations with global companies like Pfizer and AbbVie enhance access to advanced treatment options, while research organizations like Serum Institute of India and Biocon are investing in biopharmaceutical innovations that support pancreatitis management.

End User Feedback and Unmet Needs in the Global Acute Pancreatitis Market

• End users from hospitals and diagnostic centers observe gradual improvement in the care of acute pancreatitis but still highlight some areas that need to be worked on. Doctors are pleased with the newer precision treatments like CRAC channel inhibitors, which not only lower the inflammation but also speed up the recovery time, the symptom-based management being completely left behind. High-resource hospitals have managed to obtain better patients and have treatment efficacy through these advancements.
• However, there are some issues that continue to be raised regarding late diagnosis, shortage of advanced treatments for the underprivileged areas, and irregular post-acute care given to the patients. The smaller hospitals are often unable to use quick diagnosis methods or incorporate imaging. The issue of the need for quicker, less costly diagnosis and more access to breakthrough therapy is a huge opportunity for growth for both the innovators and the law makers. By bridging these gaps, innovation can be stimulated, access can be widened, and long-term patient outcomes can be more robust.

Market Players, Key Developments, and Competitive Intelligence

To learn more about this report, Download Free Sample

Key Developments

• In September 2025, Ionis Pharmaceuticals Inc., a U.S.-based biopharmaceutical company focused on RNA-targeted therapeutics, announced that its drug olezarsen significantly reduced triglyceride levels and acute pancreatitis events in Phase 3 CORE and CORE2 studies for patients with severe hypertriglyceridemia (sHTG). The trials showed up to a 72% reduction in fasting triglycerides and an 85% drop in acute pancreatitis incidents compared to placebo, marking a breakthrough in sHTG treatment.
• In August 2025, Arctx Medical Inc., a U.S.-based clinical-stage medical device company, received U.S. FDA approval for its Investigational Device Exemption (IDE) to conduct a pivotal clinical trial of its Arctx Cool Catheter (ACC) Kit for treating Acute Pancreatitis. The upcoming study will enroll around 200 patients across 25 hospitals in the U.S., following a successful First-in-Human trial involving 21 patients.
• In December 2024, Ionis Pharmaceuticals, a U.S.-based biopharmaceutical company specializing in RNA-targeted therapies, received U.S. FDA approval for TRYNGOLZA (olezarsen) as the first-ever treatment for adults with familial chylomicronemia syndrome (FCS), a rare genetic disorder causing severe hypertriglyceridemia that can lead to life-threatening acute pancreatitis.
• In September 2024, Arrowhead Pharmaceuticals, a U.S.-based biopharmaceutical company focused on RNA interference therapies, announced strong Phase 3 results from its PALISADE study of plozasiran for patients with familial chylomicronemia syndrome (FCS). The trial showed an 80% reduction in triglycerides and an 83% decrease in the risk of acute pancreatitis, marking a major milestone for a condition with no approved treatments in the U.S. Similar efficacy was seen in both genetically confirmed and clinically diagnosed FCS patients.

Top Strategies Followed by Global Acute Pancreatitis Market Players

• Market leaders rely on large R&D budgets for developing advanced diagnostics, therapeutics, and patient monitoring systems in order to stay ahead in the competition in the acute pancreatitis sector. By supporting the difficult-to-finish clinical scenarios this way, they are not only at the cutting edge technologically but also implicitly. Along with that, they are teaming up with the manufacturers, biopharmaceutical companies, and healthcare providers to jointly commercialize new products, improve production effectiveness, and quicken the market entrance for solution offerings.
  • Johnson & Johnson, Pfizer Inc., and AstraZeneca Plc lead R&D in acute pancreatitis therapies. Johnson & Johnson develops advanced endoscopic and surgical solutions for pancreatic management. Pfizer focuses on anti-inflammatory and pain-modulating drugs addressing acute pancreatitis complications. AstraZeneca explores next-generation biologics targeting pancreatic enzyme imbalance and oxidative stress pathways.

• The mid-tier companies active in the acute pancreatitis market apply different strategies that highlight cost-effectiveness and accessibility. They provide solutions that combine quality and price in such a way that the public sensitive to price, mostly in developing countries where healthcare budgets can be tight, will be reached.
  • Cala Health, Pharmaxis Ltd, and Immuron Limited exemplify mid-tier innovators. Cala Health develops neuromodulation-based solutions that indirectly assist pancreatitis symptom management. Pharmaxis focuses on small-molecule drugs that modulate inflammation and fibrosis relevant to pancreatic injury. Immuron leverages oral immunotherapy approaches to improve gut-pancreas axis function and affordability in emerging markets.

• The small market players differentiate themselves by concentrating on niche areas in the acute pancreatitis market. They emphasize on the growth of the sector by specializing in features that are developed to meet specific clinical needs or novel product applications, for example, portable diagnostic devices or the provision of customized therapeutic interventions.
  • Zymtronix Catalytic Systems, Caladrius Biosciences, and Panavance Therapeutics are niche participants. Zymtronix specializes in enzyme stabilization technologies applicable to pancreatitis enzyme formulations. Caladrius Biosciences works on regenerative cell therapies to restore pancreatic tissue. Panavance Therapeutics develops metabolic-targeting compounds (like GP-2250) for pancreatic disease modulation and supportive oncology use.

Market Report Scope

Acute Pancreatitis Market Report Coverage

Acute Pancreatitis Market Dynamics

To learn more about this report, Download Free Sample

Acute Pancreatitis Market Driver - Increasing Prevalence of Gallstone Disease

Increased gallstone disease is one of the main factors driving and influencing the global acute pancreatitis market to the most extent. Among the various causes of biliary obstruction, the leading one is gallstones and such obstructions can lead to episodes of acute pancreatitis by preventing the flow of pancreatic juice and causing inflammation in the pancreas. Among the reasons for the increasing incidence of gallstone formation all over the world are unhealthy dietary habits, such as high-fat diets, and lack of physical activity. Moreover, obesity, metabolic syndrome, and aging populations are important factors that make gallstone disease more likely which in turn leads to more cases of acute pancreatitis.

For instance, the Gastrointestinal Journal In April 2022, reported that the annual incidence of acute pancreatitis ranges from 4.9 to 35 cases per 100,000 people in the U.S. Furthermore, as per World Population Review (2022), Nauru (61%), Palau (55.3%), and the U.S. (36.2%) have the highest obesity rates globally, contributing to elevated triglyceride levels and gallstone formation major risk factors for acute pancreatitis. This growing disease burden is expected to significantly propel the acute pancreatitis market growth.

Similarly, in August 2024, according to an article published in Clinical Gastroenterology and Hepatology, gallstone disease affects around 6% of the global population, with higher rates in women and in South America. The incidence is rising at about 0.47 cases per 100 person-years, especially in upper-middle-income countries.

Acute Pancreatitis Market Opportunity - Development of Novel Targeted Therapies and Personalized Medicine

The market for global acute pancreatitis market is going to be the next big thing by new classificatory medicines and personalized therapy approaches. The inflammation of the pancreas, acute pancreatitis, presents different clinical forms and causes, making the usual treatment insufficient most of the time. The combination of molecular biology and genomics has not only revolutionized the understanding of the disease's pathophysiology but also opened the door for targeted therapeutic interventions. New drug discovery that is concentrating on specific molecular routes, like inhibitors that target inflammatory cytokines or protease activation, brings hope for better management with fewer side effects.

In September 2023, CalciMedica Inc., a U.S based clinical-stage biopharmaceutical company developing CRAC channel inhibition therapies for inflammatory and immunologic diseases, announced plans to host a virtual clinical expert’s event focused on Acute Pancreatitis. The event, held in September 2023 brought together leading clinicians including Dr. Joseph Miller of Henry Ford Health and Dr. Georgios Papachristou of The Ohio State University to discuss CalciMedica’s lead drug candidate, Auxora, and its potential role in treating Acute Pancreatitis.

Analyst Opinion (Expert Opinion)

• The acute pancreatitis market is on the rise primarily due to the increasing occurrence of gallstones, cases due to alcohol, and over-weight-related diseases. A study conducted by the National Library of Medicine (NLM) and published in May 2022 classifies the long-term use of alcohol as the second most significant cause of Acute Pancreatitis (AP) after gallstones, with a share of around 17% to 25% of worldwide cases. Moreover, the technological advancements in imaging modalities such as CT and MRI, in addition to the ongoing biomarker research, are facilitating early diagnosis and enhancing the treatment outcome. Despite the slowly improving situation, the market is still burdened with very high hospitalization costs, restricted targeted therapy options, and different reimbursement systems.
• In the larger picture, the global conferences on gastroenterology and digestive diseases have turned into platforms for introducing new concepts in pancreatic care and updating treatment guidelines. The combination of research programs aimed at alcohol-related recurrent pancreatitis and clinical testing of innovative drugs such as calcium channel blockers signifies the market's move towards preventive and precise care. All these things happening at once repair and once more displace the existing paradigm of treating conditions arising from acute crises to that of data-led, multidisciplinary therapeutic approaches that finally put the patient health first by focusing on recovery, preventing reoccurrence, and ensuring long-term health.

Market Segmentation

• Etiology Insights (Revenue, USD Bn, 2020 - 2032)
  • Gallstone-induced
  • Alcohol-induced
  • Hypertriglyceridemia-induced
  • Drug-induced
  • Post-ERCP
  • Autoimmune
  • Genetic
  • Idiopathic
• Treatment Type Insights (Revenue, USD Bn, 2020 - 2032)
  • Drug Based Therapy
    • Analgesics
    • Opioids
    • Non-opioid analgesics
    • Antiemetics
    • Proton Pump Inhibitors (PPIs)
    • Somatostatin and Analogues
    • Intravenous Fluid Therapy Agents (Lactated Ringer’s and Normal saline)
    • Pancreatic Enzyme Supplements
  • Device-Based Therapy
    • Intravenous Fluids
    • Endoscopic Retrograde Cholangiopancreatography (ERCP)
  • Nutritional Support
  • Others (Antioxidant Treatment)
• Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
  • Oral
  • Parenteral
  • Others
•  Patient Group Insights (Revenue, USD Bn, 2020 - 2032)
  • Adult
  • Pediatric
• End User Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Diagnostic Imaging Centers
  • Research and Academic Institutes
• Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Boston Scientific
  • AbbVie
  • Cook Medical
  • Medtronic
  • Olympus Corporation
  • Fujifilm Healthcare
  • Pentax Medical
  • ConMed
  • Teleflex
  • Baxter International
  • Braun Melsungen AG
  • Fresenius Kabi
  • Abbott Laboratories
  • ICU Medical
  • ERBE Elektromedizin

Sources

Primary Research Interviews

Industry Stakeholders List

• Gastroenterologists specializing in pancreatic disorders
• Pharmaceutical product managers in gastroenterology segment
• Clinical researchers involved in pancreatitis trials
• Hospital procurement officers for digestive disease therapeutics
• Medical device suppliers for endoscopic ultrasound systems
• Health economists analyzing gastrointestinal diseases

End Users List

• Pancreatitis patients under hospital-based care
• Nutrition specialists managing pancreatic insufficiency
• Intensive care unit physicians
• Laboratory technicians conducting enzyme tests
• Diagnostic imaging specialists
• Nursing supervisors in gastroenterology departments

Government and International Databases

• World Health Organization (WHO)
• U.S. Food and Drug Administration (FDA)
• Centers for Disease Control and Prevention (CDC)
• European Medicines Agency (EMA)
• National Institutes of Health (NIH)
• ClinicalTrials.gov

Trade Publications

• Pharmaceutical Technology
• BioPharm International
• Drug Development & Delivery
• PharmaTimes
• MedTech Insight
• Fierce Biotech

Academic Journals

• Pancreas (Lippincott Williams & Wilkins)
• Gastroenterology (Elsevier)
• Digestive Diseases and Sciences (Springer)
• World Journal of Gastroenterology
• Clinical Gastroenterology and Hepatology
• The American Journal of Gastroenterology

Reputable Newspapers

• The New York Times – Health Section
• The Guardian – Health
• Reuters Health
• The Washington Post – Science & Health
• Financial Times – Pharmaceuticals & Health
• The Economic Times – Healthcare

Industry Associations

• American Gastroenterological Association (AGA)
• International Association of Pancreatology (IAP)
• Digestive Disease Week (DDW) Organization
• European Pancreatic Club (EPC)
• Pancreatic Society of Great Britain and Ireland
• World Gastroenterology Organisation (WGO)

Public Domain Resources

• ScienceDirect Open Access
• National Library of Medicine (NLM)
• ResearchGate
• World Bank Health Statistics
• OpenGrey Repository

Proprietary Elements

• CMI Data Analytics Tool: Proprietary analytics tool to analyze real-time market trends, consumer behavior, and technology adoption in market
• Proprietary CMI Existing Repository of Information for Last 8 Years